Clinical Pharmacokinetics

, Volume 56, Issue 11, pp 1415–1427 | Cite as

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

  • Amparo de la Peña
  • Xuewei Cui
  • Jeanne Geiser
  • Corina Loghin
Original Research Article



Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.


In four separate clinical pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated.


Areas under the concentration–time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin, where it was reduced by 21%. Maximum concentrations (C max) were generally lower following coadministration with dulaglutide, with statistically significant reductions (90% confidence intervals of geometric least squares means ratios outside 0.80–1.25) for all analytes except R-warfarin. For all analytes, there was a general trend for the time to C max (t max) to increase following coadministration with dulaglutide. For warfarin, dulaglutide coadministration had no statistically significant effect on the maximum INR (INRmax); however, a 2% increase in area under the INR curve (AUCINR) was observed.


Dulaglutide did not affect the absorption of the tested medications to a clinically relevant degree. Based on the PK and PD evaluations, no dose adjustments for digoxin, warfarin, atorvastatin and Ortho-Cyclen® are recommended when coadministered with dulaglutide.

Clinical trial registration numbers

NCT01458210, NCT01436201, NCT01432938, and NCT01250834.


Warfarin Digoxin Atorvastatin Gastric Emptying International Normalize Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank the trial investigators, trial staff, and trial participants for their contributions. They would also like to express their gratitude to Dr. Helen Salter and Dr. Mark Stead for providing medical writing support, and Dr. Jenny Chien for providing scientific review and technical support.

Compliance with ethical standards


This work was sponsored by Eli Lilly and Company.

Conflict of interest

Amparo de la Peña, Xuewei Cui, Jeanne Geiser, and Corina Loghin are employees and shareholders of Eli Lilly and Company.

Scientific meeting presentation

This work was presented in part at the annual meetings of the American Association of Clinical Endocrinologists (AACE), Nashville, TN, USA, 13–17 May 2015, and the American Society for Clinical Pharmacology and Therapeutics (ASCPT), New Orleans, LA, USA, 3–7 March 2015.


  1. 1.
    Trulicity (prescribing information). Lilly USA, LLC, Indianapolis; 2014. Accessed 1 Sep 2016.
  2. 2.
    Trulicity (summary of product characteristics). Eli Lilly Nederland BV, Utrecht; 2014. Accessed 21 Oct 2016.
  3. 3.
    Faraj J, Melander O, Sundkvist G, Olsson R, Thorsson O, Ekberg O, et al. Oesophageal dysmotility, delayed gastric emptying and gastrointestinal symptoms in patients with diabetes mellitus. Diabet Med. 2007;24(11):1235–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Jones KL, Horowitz M, Wishart JM, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med. 1995;36(12):2220–8.PubMedGoogle Scholar
  5. 5.
    Stacher G, Lenglinger J, Bergmann H, Schneider C, Brannath W, Festa A, et al. Impaired gastric emptying and altered intragastric meal distribution in diabetes mellitus related to autonomic neuropathy. Dig Dis Sci. 2003;48(6):1027–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Woodyatt RT, Sansum WD, Wilder RM. Prolonged and accurately timed intravenous injection of sugar. JAMA. 1915;65(24):2067–70.CrossRefGoogle Scholar
  7. 7.
    Gonlachanvit S, Hsu CW, Boden GH, Knight LC, Maurer AH, Fisher RS, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci. 2003;48(3):488–97.CrossRefPubMedGoogle Scholar
  8. 8.
    Thompson DG, Wingate DL, Thomas M, Harrison D. Gastric emptying as a determinant of the oral glucose tolerance test. Gastroenterology. 1982;82(1):51–5.PubMedGoogle Scholar
  9. 9.
    O’Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3431–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–20.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004;91:439–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151(1–3):123–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48(11):1494–501.CrossRefPubMedGoogle Scholar
  16. 16.
    Loghin C, de la Peña A, Cui X, Chien J. Gastric emptying effects of once weekly dulaglutide in patients with type 2 diabetes mellitus (poster). Presented at the American Association of Clinical Endocrinologists, 23rd annual scientific and clinical congress, 14–18 May 2014, Las Vegas.Google Scholar
  17. 17.
    Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Lanoxin (prescribing information). Covis Pharmaceuticals Inc.; 2015. 21 Oct 2016.
  19. 19.
    Coumadin (prescribing information). Bristol-Myers Squibb Company; 2016. Accessed 21 Oct 2016.
  20. 20.
    O’Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest. 1963;42(10):1542–51.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, et al. Effect ofexenatideon the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46(10):1179–87.CrossRefPubMedGoogle Scholar
  22. 22.
    Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587–603.CrossRefPubMedGoogle Scholar
  23. 23.
    Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Lipitor (prescribing information). Pfizer Inc.; 2015. Accessed 21 Oct 2016.
  25. 25.
    Ortho-Cyclen (prescribing information). Janssen Pharmaceuticals, Inc.; 2015.,019697s052,021690s001lbl.pdf. Accessed 21 Oct 2016.
  26. 26.
    Steinijans VW, Sauter R, Hauschke D, Diletti E, Schall R, Luus HG, et al. Reference tables for the intrasubject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther. 1995;33(8):427–30.PubMedGoogle Scholar
  27. 27.
    Stern RH, Smithers JA, Olsen SC. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. J Clin Pharmacol. 1998;38(8):753–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kearney BP, Mathias A. Lack of effect of tenofovirdisoproxilfurmarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009;29(8):924–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Narwal R, Akhlaghi F, Asberg A, Hermann M, Rosenbaum SE. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Clin Pharmacokinet. 2010;49(10):693–702.CrossRefPubMedGoogle Scholar
  31. 31.
    Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Schoetzau A, Leese PT, et al. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinylestradiol/norgestimate. Clin Exp Dermatol. 2011;36(2):4–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012;12(8):1–9.Google Scholar
  33. 33.
    US FDA. Guidance for industry. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. US FDA; 2012.Google Scholar
  34. 34.
    Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Hurren KM, Pinelli NR. Drug–drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012;46(5):710–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Eli Lilly and Company, Lilly Corporate CenterIndianapolisUSA

Personalised recommendations